GGrantIndex
← Leaderboards

David J Bzik

Dartmouth College

$12,242,064
Attributed
$12,448,569
Total exposure
18
Grants
16
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $908.4K · FY200525
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,448,569 · 18

By mechanism

R21$7,016,037 · 16
R01$5,432,532 · 2

Top collaborators

Others in their field

Top investigators on “Toxoplasma Gondii

Research focus

Toxoplasma GondiiParasitesPreventBiologyInfectionToxoplasmosisCystAcquired Immunodeficiency SyndromeAcuteMutantChronicGeneticBiologicalCellsIn VivoLifeVirulenceImmuneToxoplasmaIn VitroImmune ResponseEncephalitisPharmaceutical PreparationsProteins

Grant awards (47)

Metabolic basis for the persistence of dormant Toxoplasma gondii infection$397,700
R01 · FY2025 · AI · contact PI
Metabolic basis for the persistence of dormant Toxoplasma gondii infection$409,167
R01 · FY2024 · AI · contact PI
Metabolic basis for the persistence of dormant Toxoplasma gondii infection$407,916
R01 · FY2023 · AI · contact PI
Glucosylation Regulates Cyst Wall Formation, Stability, and Persistence of the AIDS Pathogen Toxoplasma gondii$247,435
R21 · FY2022 · AI · contact PI
Iron regulation of chronic Toxoplasma gondii infection and immunity$219,075
R21 · FY2022 · AI
Novel vacuole biology in chronic Toxoplasma infection$246,000
R21 · FY2021 · AI · contact PI
Intravacuolar network dense granule protein biology in chronic Toxoplasma infection$246,000
R21 · FY2021 · AI · contact PI
Glucosylation Regulates Cyst Wall Formation, Stability, and Persistence of the AIDS Pathogen Toxoplasma gondii$222,435
R21 · FY2021 · AI · contact PI
Iron regulation of chronic Toxoplasma gondii infection and immunity$193,935
R21 · FY2021 · AI
Intravacuolar network dense granule protein biology in chronic Toxoplasma infection$205,000
R21 · FY2020 · AI · contact PI
Novel vacuole biology in chronic Toxoplasma infection$205,000
R21 · FY2020 · AI · contact PI
Genetic models for latent Toxoplasma gondii infection$243,000
R21 · FY2019 · AI · contact PI
Novel virulence function in Toxoplasma chronic infection$243,000
R21 · FY2019 · AI · contact PI
Novel rhoptry protein function in chronic toxoplasma infection$243,000
R21 · FY2018 · AI · contact PI
Genetic models for latent Toxoplasma gondii infection$202,500
R21 · FY2018 · AI · contact PI
Novel virulence function in Toxoplasma chronic infection$202,500
R21 · FY2018 · AI · contact PI
Novel rhoptry protein function in chronic toxoplasma infection$202,500
R21 · FY2017 · AI · contact PI
Dense granule protein virulence factors in Toxoplasma gondii infection$243,000
R21 · FY2015 · AI · contact PI
Toxoplasma gondii GRA protein function$243,000
R21 · FY2014 · AI · contact PI
Parasite secreted proteins control host response to Toxoplasma gondii infection$243,000
R21 · FY2014 · AI · contact PI
Dense granule protein virulence factors in Toxoplasma gondii infection$202,500
R21 · FY2014 · AI · contact PI
T. Gondii: Pyrimidine Synthesis as a Chemo Target$363,912
R01 · FY2013 · AI · contact PI
Parasite secreted proteins control host response to Toxoplasma gondii infection$201,979
R21 · FY2013 · AI · contact PI
Toxoplasma gondii GRA protein function$190,155
R21 · FY2013 · AI · contact PI
T. Gondii: Pyrimidine Synthesis as a Chemo Target$387,140
R01 · FY2012 · AI · contact PI
Genetic dissection of the Toxoplasma gondii rhoptry kinome$237,000
R21 · FY2012 · AI · contact PI
T. Gondii: Pyrimidine Synthesis as a Chemo Target$387,140
R01 · FY2011 · AI · contact PI
Functional analysis of CD8 T cell immune control in Toxoplasma gondii infection$234,630
R21 · FY2011 · AI · contact PI
Genetic dissection of the Toxoplasma gondii rhoptry kinome$197,500
R21 · FY2011 · AI · contact PI
T. Gondii: Pyrimidine Synthesis as a Chemo Target$391,050
R01 · FY2010 · AI · contact PI
Genetic models for post-genome functional analysis of Toxoplasma gondii$237,000
R21 · FY2010 · AI · contact PI
Functional analysis of CD8 T cell immune control in Toxoplasma gondii infection$197,500
R21 · FY2010 · AI · contact PI
T. Gondii: Pyrimidine Synthesis as a Chemo Target$396,188
R01 · FY2009 · AI · contact PI
Regulated virulence and cyst maturation in Toxoplasma gondii$239,850
R21 · FY2009 · AI · contact PI
Genetic models for post-genome functional analysis of Toxoplasma gondii$197,500
R21 · FY2009 · AI · contact PI
Enhanced homologous recombination in Toxoplasma gondii$235,293
R21 · FY2008 · AI · contact PI
Regulated virulence and cyst maturation in Toxoplasma gondii$199,875
R21 · FY2008 · AI · contact PI
T.gondii pyrimidine synthesis as a chemotherapy target$337,079
R01 · FY2007 · AI · contact PI
Enhanced homologous recombination in Toxoplasma gondii$199,875
R21 · FY2007 · AI · contact PI
T.gondii pyrimidine synthesis as a chemotherapy target$347,147
R01 · FY2006 · AI · contact PI
T.gondii pyrimidine synthesis as a chemotherapy target$355,500
R01 · FY2005 · AI
T.gondii pyrimidine synthesis as a chemotherapy target$355,500
R01 · FY2004 · AI
T.gondii pyrimidine synthesis as a chemotherapy target$355,500
R01 · FY2003 · AI
Attenuated T.gondii as a Vector for HIV Vaccines$197,500
R21 · FY2003 · AI
Attenuated T.gondii as a Vector for HIV Vaccines$197,500
R21 · FY2002 · AI
T GONDII--PYRIMIDINE SYNTHESIS AS A CHEMOTHERAPY TARGET$274,797
R01 · FY2001 · AI
T GONDII--PYRIMIDINE SYNTHESIS AS A CHEMOTHERAPY TARGET$266,796
R01 · FY2000 · AI